×
About 8,390 results

ALLMedicine™ Aspartate Aminotransferase Center

Research & Reviews  2,898 results

Retrospective study of the influence of hypothyroidism on liver function before radioio...
https://doi.org/10.1136/bmjopen-2020-045562
BMJ Open; Ji Y, Zheng W et. al.

Jan 20th, 2022 - The aim of the present study is to investigate the risk factors for hepatic dysfunction before radioiodine therapy in patients with differentiated thyroid cancer (DTC). 996 patients (314 men, 682 women; age of 45.07±12.98 years) with postoperative...

Machine Learning Algorithms for Predicting Direct-Acting Antiviral Treatment Failure in...
https://doi.org/10.1002/hep.32347
Hepatology (Baltimore, Md.); Park H, Lo-Ciganic WH et. al.

Jan 17th, 2022 - We aimed to develop and validate machine learning algorithms to predict direct-acting antiviral (DAA) treatment failure among patients with hepatitis C virus (HCV) infection. We used HCV-TARGET registry data to identify HCV-infected adults receivi...

Association between urine metals and liver function biomarkers in Northeast China: A cr...
https://doi.org/10.1016/j.ecoenv.2022.113163
Ecotoxicology and Environmental Safety; Zhao M, Ge X et. al.

Jan 15th, 2022 - After heavy metals enter the body, they affect a variety of organs, particularly the main metabolic organ, the liver. Moreover, people are more likely to be exposed to multiple metals than to a single metal. We explored the associations between ex...

Oxidative stress and biochemical indicators in blood of patients addicted to alcohol tr...
https://doi.org/10.1177/09603271211061502
Human & Experimental Toxicology; Sommerfeld-Klatta K, Łukasik-Głębocka M et. al.

Jan 14th, 2022 - Ethylene glycol (EG), in addition to its neurotoxic and nephrotoxic effects, evokes oxidative stress. The aim of this study was to assess the influence of the ethylene glycol on the biochemical indicators and oxidoreductive balance of patients tre...

see more →

Guidelines  1 results

ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries.
https://doi.org/10.1038/ajg.2016.517
The American Journal of Gastroenterology; Kwo PY, Cohen SM et. al.

Dec 21st, 2016 - Clinicians are required to assess abnormal liver chemistries on a daily basis. The most common liver chemistries ordered are serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase and bilirubin. These tests sh...

see more →

Drugs  29 results see all →

Clinicaltrials.gov  87 results

RiteStart Personal Nutritional Dietary Study
https://clinicaltrials.gov/ct2/show/NCT05130905

Nov 23rd, 2021 - Blood samples were drawn by a certified phlebotomist, prepared, and then analyzed by a Clinical Laboratory Improvement Amendments (CLIA)-certified independent laboratory. The following components were measured in sera from the participants: Alanin...

FAST PV and mGFR™ Technology in Congestive Heart Failure
https://clinicaltrials.gov/ct2/show/NCT03808948

Nov 17th, 2021 - This investigator-initiated, one-armed study is designed to evaluate the safety and function of the FAST PV and mGFR Technology in patients with CHF. Data from the FAST PV and mGFR Technology will not be evaluable by the treating physician, but wi...

XmAb18968 (CD3-CD38) in Relapsed or Refractory Acute Leukemia and T Cell Lymphoblastic Leukemia
https://clinicaltrials.gov/ct2/show/NCT05038644

Nov 11th, 2021 - The primary objective of this portion of the study is to determine a recommended phase II dose (RP2D) for XmAb18968. The trial will use a variation of the 3 + 3 design where both escalation and de-escalation are possible. There will be separate co...

Deoxynucleosides Pyrimidines as Treatment for Mitochondrial Depletion Syndrome
https://clinicaltrials.gov/ct2/show/NCT04802707

Nov 4th, 2021 - This Trial is designed as Phase II, Monocenter, Open label study in the pediatric population. The aim is to evaluate the safety, tolerability and efficacy of Deoxycytidine and Deoxythymidine in treatment of children with Mitochondrial Depletion Di...

Cigarette Smoking in Non-alcoholic Steatohepatitis
https://clinicaltrials.gov/ct2/show/NCT04688307

Oct 21st, 2021 - After excluding other causes of high aminotransferase level, participants with persistent elevated serum aminotransferase levels and evidence of fatty liver in ultrasonography were presumed to have non-alcoholic steatohepatitis. Those with NAFLD l...

see more →

News  341 results

FDA Accepts BLA for Tislelizumab in Esophageal Squamous Cell Carcinoma
https://www.onclive.com/view/fda-accepts-bla-for-tislelizumab-in-esophageal-squamous-cell-carcinoma

Jan 14th, 2022 - The FDA has accepted for review a biologics license application (BLA) for tislelizumab (BGB-A317) as a potential therapeutic option in patients with unresectable recurrent locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) fo...

FDA Grants Fast Track Designation to Enobosarm for AR+/ER+ Metastatic Breast Cancer
https://www.onclive.com/view/fda-grants-fast-track-designation-to-enobosarm-for-ar-er-metastatic-breast-cancer

Jan 10th, 2022 - The FDA has granted a fast track designation to enobosarm as a potential therapeutic option for patients with androgen receptor (AR)–positive, estrogen receptor (ER)–positive, HER2-negative, metastatic breast cancer who progressed on a nonsteroida...

Immune Checkpoint, VEGFR Inhibitor Combo Effective in Advanced Esophageal Cancer
https://www.medpagetoday.com/hematologyoncology/othercancers/96587

Jan 10th, 2022 - A combination of the novel PD-1 inhibitor camrelizumab and the novel VEGFR-2 inhibitor apatinib achieved encouraging outcomes in second-line treatment of advanced esophageal squamous cell carcinoma in a single-arm, open-label, phase II trial from ...

CLN-081 Granted FDA Breakthrough Therapy Designation Status for EGFR-Mutated NSCLC
https://www.onclive.com/view/cln-081-granted-fda-breakthrough-therapy-designation-status-for-egfr-mutated-nsclc

Jan 4th, 2022 - The FDA has granted breakthrough therapy designation to CLN-081 (TAS6417) for the treatment of patients with locally advanced or metastatic non–small cell lung cancer harboring EGFR exon 20 insertion mutations and who have received prior platinum-...

Trastuzumab Deruxtecan Bests T-DM1 in First Head-to-Head Study for HER2+ Breast Cancer
https://www.onclive.com/view/trastuzumab-deruxtecan-bests-t-dm1-in-first-head-to-head-study-for-her2-breast-cancer

Dec 13th, 2021 - Fam-trastuzumab deruxtecan-nxki (Enhertu) demonstrated a clinically meaningful and statistically significant improvement in progression-free survival (PFS) vs standard of care trastuzumab emtansine (T-DM1; Kadcyla) for patients with previously tre...

see more →